No Data
No Data
Bloomage Biotechnology Corporation Limited (688363): Profitability under temporary pressure, new medical aesthetic products launch is expected to drive growth.
Event description: In Q3 2024, the company achieved revenue of 1.064 billion yuan, a year-on-year decrease of 7.1%; net income attributable to the parent company was 20.26 million yuan, a year-on-year decrease of 77.4%; and non-recurring net income attributable to the parent company was 10.58 million yuan, a year-on-year decrease of 8.
Express News | 7 listed companies' stocks were reduced by important shareholders, with bloomage biotechnology corporation limited having the highest amount of shareholding reduction.
Bloomage Biotechnology Corporation Limited (688363.SH): China Life Insurance and Chengda collectively shareholding 1.00% of the company's shares.
On November 11, GlonHe announced that Bloomage Biotechnology Corporation Limited (688363.SH) disclosed that as of November 11, 2024, China Life Chengda reduced its holdings of the company's shares by 4,634,782 shares through centralized bidding trading, and reduced its holdings of the company's shares by 182,000 shares through block trading, with a total reduction of 4,816,782 shares, accounting for 1.00% of the total number of company shares. After this equity change, China Life Chengda holds 29,616,504 shares of the company, accounting for 6.15% of the total number of company shares.
Express News | A-share restricted shares to be lifted: 18.608 billion yuan market cap restricted shares to be lifted today.
gtja: In Q3, the retail sales of cosmetics decreased month-on-month during the off-season. The Hong Kong stock beauty companies' positions increased month-on-month.
In the third quarter, the cosmetic industry has a relatively dispersed structure, with significant differences in the operating pace of each company against the backdrop of overall weak demand in the industry.
Express News | Next week, the market cap of A shares to be unlocked is approximately 27.7 billion yuan.
No Data